Literature DB >> 7509037

Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc.

S M Dilworth1, C E Brewster, M D Jones, L Lanfrancone, G Pelicci, P G Pelicci.   

Abstract

Polyoma virus middle T-antigen converts normal fibroblasts to a fully transformed, tumorigenic phenotype. It achieves this, at least in part, by binding and activating one of the non-receptor tyrosine kinases, pp60c-src, pp62c-yes or pp59c-fyn (reviewed in refs 2 and 3). As a result, middle T-antigen itself is phosphorylated on tyrosine residues, one of which (Tyr 315) acts as a binding site for the SH2 domains of phosphatidylinositol-3'OH kinase 85K subunit. Here we show that another tyrosine phosphorylation site in middle T-antigen (Tyr 250; refs 4, 5) acts as a binding region for the SH2 domain of the transforming protein Shc. This results in Shc also becoming tyrosine-phosphorylated and binding to the SH2 domain of Grb2 (ref. 10). This probably stimulates p21ras activity through the mammalian homologue of the Drosophila guanine-nucleotide-exchange factor Sos (reviewed in ref. 11). We suggest that middle T-antigen transforms cells by acting as a functional homologue of an activated tyrosine kinase-associated growth-factor receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7509037     DOI: 10.1038/367087a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  77 in total

1.  Middle T antigen activation of signal transduction pathways does not overcome p53-mediated growth arrest.

Authors:  J Doherty; R Freund
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  ShcA tyrosine phosphorylation sites can replace ShcA binding in signalling by middle T-antigen.

Authors:  P R Nicholson; S Empereur; H R Glover; S M Dilworth
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

Review 3.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

4.  Tumor induction by a transformation-defective polyoma virus mutant blocked in signaling through Shc.

Authors:  R Bronson; C Dawe; J Carroll; T Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

5.  Evidence for a requirement for both phospholipid and phosphotyrosine binding via the Shc phosphotyrosine-binding domain in vivo.

Authors:  K S Ravichandran; M M Zhou; J C Pratt; J E Harlan; S F Walk; S W Fesik; S J Burakoff
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

6.  CD3-epsilon overexpressed in prothymocytes acts as an oncogene.

Authors:  B Wang; J She; M Salio; D Allen; E Lacy; N Lonberg; C Terhorst
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

7.  Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras.

Authors:  N P Klein; R J Schneider
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

8.  Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene.

Authors:  M A Webster; R D Cardiff; W J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

9.  The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor.

Authors:  A G Batzer; P Blaikie; K Nelson; J Schlessinger; B Margolis
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

10.  Association of insulin receptor substrate 1 with simian virus 40 large T antigen.

Authors:  Z L Fei; C D'Ambrosio; S Li; E Surmacz; R Baserga
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.